
Evidence of deliberate climate damage
For decades, some members of the fossil fuel industry tried to convince the public that a causative link between fossil fuel use and climate warming...

HOOKIPA bags US$10m cancer milestone
The Vienna-based arenavirus specialist got the non-dilutive milestone payment for advancing its drug programme HB-700, a novel arenaviral...

Collaboration to develop mRNA vaccine against betacoronaviruses
Ethris GmbH a German company specialising in the development of mRNA vaccines, announced their collaboration with DIOSynVax Ltd., an English biotech...

Rewind Therapeutics extends Series A financing
The company, founded by CD3 (Leuven, Belgium) and Axxam S.p.A. (Milan), did not want to reveal the exact amount added to the €15.2m in its 2018...

Neurodegenerative disorders are being fought with €28m
The Danish biotech Teitur Trophics ApS, aiming to treat chronic neurological disorders, has completed a €28m Series A funding. With the money, Teitur...

European VCs join US$105m financing of US Mediar Thx
Fibrosis, triggered by inflammation or injury, results in an abnormal production of scar tissue that can lead to organ failure. Luckily, not all...

€72M from Novo´s REPAIR Impact Fund for Group B Streptococcus vaccines
Group B Streptococcus (GBS) colonises globally about 15-25% of women and can cause life-threatening infections in newborns during the first months of...